Kernodle & Katon Asset Management Group’s United Therapeutics UTHR Stock Holding History

Kernodle & Katon Asset Management Group’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1K	Buy	+10	New	+$1.51K	﹤0.01%	314

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kernodle & Katon Asset Management Group's UTHR Position: Q1 2017 in Review

Kernodle & Katon Asset Management Group opened a new position in United Therapeutics (UTHR) in Q1 2017: 10 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #314 among its holdings.

411 funds tracked by Wall St. Rank hold UTHR as of Q1 2017.

Kernodle & Katon Asset Management Group held 10 shares of United Therapeutics worth $1K as of Q1 2017.
United Therapeutics was a new Kernodle & Katon Asset Management Group position in Q1 2017.
United Therapeutics made up ﹤0.01% of Kernodle & Katon Asset Management Group's portfolio in Q1 2017, its #314 holding.
411 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2017.

Based on Kernodle & Katon Asset Management Group's 13F filing for Q1 2017, filed 12 May 2017.